within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01C_BetaLactamAntibacterialsPenicillins.J01CA09_Azlocillin;

model Azlocillin
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 3e-06,
    adminDuration = 600,
    adminMass = 5000 / 1000000,
    adminCount = 1,
    Vd = 0.0135,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.0081,
    k12 = 1.75e-06,
    k21 = 1.75e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Azlocillin</td></tr><tr><td>ATC code:</td><td>J01CA09</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>5000</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>13.5</td><td>L</td></tr>
    <tr><td>clearance:</td><td>10.8</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Azlocillin is a semisynthetic, broad-spectrum penicillin antibiotic of the ureidopenicillin class. It has strong activity against Gram-negative bacteria including Pseudomonas aeruginosa and some Gram-positive organisms. It is typically used for severe infections or hospital-acquired infections. Azlocillin is not widely used today, with its approval status restricted or withdrawn in many countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after single intravenous dose.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.J.J01CA09 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Azlocillin;
